INTRODUCTION
Kaposi sarcoma herpesvirus (KSHV) associated multicentric Castleman disease (KSHV-MCD) is a lymphoproliferative disorder characterized by inflammatory symptoms, cytopenias, lymphadenopathy, splenomegaly and a waxing and waning course that is eventually lethal if untreated [1, 2] . It is caused by KSHV, also called human herpesvirus 8 (HHV-8) [1] , which is also the etiologic agent of Kaposi sarcoma [3] , primary effusion lymphoma (PEL) [4, 5] and a recently described interleukin 6 (IL-6) related disease called KSHV-inflammatory cytokine syndrome (KICS) [6,7 & ]. KSHV-MCD is one form of a cluster of diseases called Castleman disease. Benjamin Castleman first described angiofollicular lymph node hyperplasia in localized mediastinal masses in a disease now considered a hyaline vascular variant of Castleman disease (HV-CD) [8, 9] . Variants with expansion of plasmacytic [10] or plasmablastic cells [11] were subsequently described and also called Castleman disease. Most plasmacytic or plasmablastic Castleman disease cases are multicentric and remarkable for IL-6-associated inflammatory symptoms [2, 12, 13] . However, some cases of plasmacytic or plasmablastic Castleman disease are unicentric, and HV-CD may occasionally be multicentric [14, 15] . After discovery of KSHV [3] , it was appreciated that most plasmablastic MCD arising in effusions, PEL should be excluded through evaluation of cytopathology, Epstein-Barr virus and KSHV, flow cytometry and B-cell clonality [38, 39] .
EPIDEMIOLOGY OF KAPOSI SARCOMA HERPESVIRUS-MULTICENTRIC CASTLEMAN DISEASE
Although KSHV-MCD is considered to be extremely rare, its incidence and prevalence are uncertain. It is not tracked in cancer registries. Given its nonspecific symptoms and a waxing and waning course, KSHV-MCD is almost certainly underrecognized. Unlike Kaposi sarcoma, whose incidence decreased with broad availability of highly active antiretroviral therapy (HAART) [40 & ], the incidence of KSHV-MCD appears to be increasing in the HAART era [41] . Biologically, this is plausible. Unlike Kaposi sarcoma that is associated with degree of immunosuppression [42] and lack of KSHV specific T-cell response [43] [44] and elevated levels of antibodies directed against KSHV capsid protein K8.1 [45] .
There are almost no reports of KSHV-MCD in sub-Saharan Africa, despite high prevalence of both HIV and KSHV [46,47,48 && ]. This likely reflects underdiagnosis and underreporting of KSHV-MCD; indeed, of 32 cases of KSHV-MCD followed at the NIH Clinical Center in Bethesda, Maryland, USA, five were in recent African immigrants (Uldrick, Polizzotto, and Yarchoan, unpublished observation) . Additional studies are needed to define the incidence and prevalence of KSHV-MCD in different populations.
PATHOGENESIS OF KAPOSI SARCOMA HERPESVIRUS-MULTICENTRIC CASTLEMAN DISEASE
Like other herpesviruses, KSHV has two principal phases of gene expression: a latent phase, and a lytic phase in which production of new virions occurs. Latency-associated nuclear antigen (LANA) and other latent genes, as well as 12 KSHV encoded microRNA (miRNA) are expressed in both phases, whereas lytic genes are generally expressed only during the lytic phase. Certain genes, such as KSHV-encoded viral IL-6 (vIL-6), are predominantly released during lytic replication but can also be produced in small amounts during latent infection [49] . In all MCD, the main pathological process is B-cell hyperproliferation, caused in part by autocrine and paracrine signaling and symptoms and laboratory abnormalities are related to increased levels of IL-6 [2, 6] . In KSHV-MCD, there is also production of KSHV-encoded vIL-6 with detectable levels in the serum, and this is believed to be an important cause of disease manifestations [6, 50] . Unlike human IL-6, which first binds a coreceptor, gp80, and then to gp130, vIL-6 signals directly through gp130 [51] [52] [53] [54] [55] [56] [57] [58] , and thus potentially affects a wider range of cells than human IL-6. In addition, KSHV-MCD pathogenesis may involve upregulation of NF-kB by latently expressed viral-FLICE inhibitory protein (vFLIP) [59, 60] or viral miRNA-K1 [61] , and upregulation of VEGF and other factors by a viral G-protein coupled receptor [59] [60] [61] [62] . Patients with KSHV-MCD also frequently have elevated serum IL-10 and other cytokine abnormalities. The relative contribution of these various factors to KSHV-MCD ( [82] , that are monotypic (l-restricted) but polyclonal, and a larger population of KSHVuninfected B cells [11, 83] . All KSHV-infected cells express LANA, whereas a portion also express vIL-6 or other lytic genes [84] [85] [86] .
KSHV has tropism for B cells, monocytes, dendritic cells, epitehelial, keratinocytes and endothelial cells [87] [88] [89] [90] . Infection of target cells is complex [91] ; xCT, integrin a3b1 [92] [93] [94] and DC-SIGN [95, 96] can function as receptors for KSHV entry. B-cell infection by KSHV is enhanced by activation signals such as IL-4 and CD40-ligand [95] [96] [97] . Stable B-cell infection in vitro predominantly occurs in IgM þ , l-restricted B cells with a 'blasting' morphology that is promoted by IL-6, recapitulating lymph node findings [98 && ]. There is evidence that vFLIP plays a role in the bias toward l-restriction [65 && ]. Additional efforts to dissect interactions between specific KSHV genes and human genes associated with plasmablast differentiation [82, 99, 100] may provide insights into disease pathogenesis. KSHV-MCD patients also tend to have certain KSHV miRNA polymorphisms [101 && ], and further assessment of these findings as well as assessment of polymorphisms in other KSHV genes or the host genome affecting IL-6 signaling is warranted.
More recently, we described a group of patients with MCD-like fever and inflammatory symptoms, elevated serum vIL-6, and elevated KSHV viral load, but without pathological findings of KSHV-MCD [6] ; this syndrome has been tentatively named KSHV-associated inflammatory cytokine syndrome (KICS) [7 & ]. Studies to evaluate its natural history, pathogenesis and relation to KSHV-MCD are underway (NCT01419561).
THERAPY FOR KAPOSI SARCOMA HERPESVIRUS-MULTICENTRIC CASTLEMAN DISEASE
There is currently no established therapy for KSHV-MCD. Until recently, most published literature consisted of case reports or small case series. Although HAART has not been formally studied, a strong case can be made for its use concurrent with specific therapy in HIV-infected patients with KSHV-MCD [30, 102] . Additional specific treatment of KSHV-MCD is generally reserved for patients with symptomatic disease. Such patients can become critically ill, and may require urgent treatment and supportive care, in an ICU if needed. Successful treatment has been reported with various chemotherapeutic agents, including etoposide, vincristine, vinblastine, cyclophosphamide or doxorubicin, either as singly or in combination. Likewise, temporary remission of symptoms after splenectomy has been described, although splenectomy in HIV-infected patients carries a high risk of infectious complications [31,103,104 && ]. Steroids may reduce inflammation in symptomatic patients; however, their utility is limited, and prolonged use commonly exacerbates Kaposi sarcoma [105] . Immunomodulation with interferon-a [31, 106, 107] and thalidomide [108] has also been noted to have activity. With most of these modalities, relapse is common, and until recently, overall survival has been poor; a pooled evaluation of 86 cases between 1985 and 2006 reported a median survival of about 12 months, although somewhat better in patients on HAART [102] .
In the past several years, targeted approaches have been prospectively evaluated in KSHV-MCD. Results suggest improved outcomes over most modalities listed above. In clinical studies, several criteria have been employed for initiating therapy (Table 2) , generally including elevated CRP and at least two to four clinical and laboratory abnormalities. Importantly, patients were not treated based on abnormal radiographic findings alone. Also, there are no commonly used response criteria. Investigators have primarily graded responses in relation to resolution of clinical symptoms and laboratory abnormalities. In an attempt to establish response criteria for KSHV-MCD, we prospectively evaluated KSHV-MCD response criteria that integrate clinical, common biochemical and radiographic findings [32 && ]. Further efforts to harmonize response criteria among clinical trials are needed.
Radiographic responses and KSHV viral load dynamics have generally been evaluated as secondary outcomes [32 && ,109,110] . Importantly, residual adenopathy, splenomegaly and detectable KSHV viral load have been noted even after resolution of symptoms. Such patients may represent a group with reservoirs of KSHV-infected B cells that are inadequately treated, and who may be at higher risk of recurrent KSHV-MCD symptoms [111 & ]. Nonetheless, optimal duration of therapy and approach to such patients remains an area of uncertainty.
Rituximab
The best-studied agent in KSHV-MCD is rituximab, a humanized monoclonal antibody against the B-cell antigen CD20. Rituximab has been evaluated in two prospective phase 2 studies. In the CastlemaB Study, 24 patients with HIV and KSHV-MCD received rituximab 375 mg/m 2 weekly for 4 weeks after completion of chemotherapy [109] . Ninety-two percent of patients met the primary outcome of sustained resolution of their MCD attack ( Table 2) 60 days after completion of chemotherapy. In eight of 10 evaluated patients, splenomegaly resolved, and at 1 year, 71% were alive and disease-free [109] . In a separate study, 21 patients with symptomatic KSHV-MCD were treated with rituximab 375 mg/m 2 weekly for 4 weeks without chemotherapy [110] . Ninety-five percent had resolution of symptoms and fever, with an estimated 79% of patients relapse-free at 2 years. In the latter study, none had a complete radiographic response by Response ] included additional liver function abnormalities, leukopenia, hyponatremia, and elevated creatinine as potential laboratory abnormalities. From clinical trial NCT00099073. b Adapted with permission from [109] .
Evaluation Criteria in Solid Tumors criteria. However, KSHV viral load and CRP decreased significantly 1 month after completion of therapy [110] .
Infusion reactions occur in most KSHV-MCD patients administered rituximab [109] . Additionally, rituximab is associated with worsening Kaposi sarcoma in 35-67% of patients [109, 110] . The pathophysiology of Kaposi sarcoma relapses is unknown, but likely due to adverse immunologic effects of B-cell depletion [45, [112] [113] [114] [115] . Risk of additional rare but serious infectious complications persist beyond dosing of rituximab [116, 117] . Importantly, combination of rituximab with cytotoxic chemotherapy may be required for some patients with concurrent Kaposi sarcoma or severe manifestations of KSHV-MCD [118] [119] [120] . To address the issue of Kaposi sarcoma relapse, and to potentially also target Kaposi sarcoma spindle cells or monocytes that may be secreting vIL-6, we are currently evaluating rituximab in combination with liposomal doxorubicin in patients with concurrent KSHV-MCD and Kaposi sarcoma or severe KSHV-MCD (NCT00099073).
Interestingly, the mechanism of action of rituximab in KSHV-MCD is unclear. KSHV-infected, vIL-6 expressing plasmablasts in KSHV-MCD [85, 86] are generally CD20 negative and unlikely to be directly targeted by rituximab [82, 121] . However, CD20 þ cells are noted in KSHV-uninfected lymphocytes within lymph node specimens [11] (Fig. 2) , and rituximab activity likely results in part from diminished autocrine and paracrine signaling in the tumor microenvironment [122] [123] [124] [125] [126] [127] .
Ganciclovir and other inhibitors of Kaposi sarcoma herpesvirus replication
Ganciclovir is a 2 0 -deoxyguanosine nucleoside analogue phosphorylated by several herpesvirus thymidine kinases, including KSHV ORF36 [128] [129] [130] and ORF21 [128, 129] . Ganciclovir triphosphate inhibits viral replication through incorporation into viral DNA and subsequent chain termination. Valganciclovir (VGC), an oral prodrug, decreases KSHV oral shedding [72] . In a case series of three patients with KSHV-MCD, ganciclovir administration led to at least short-term improvement in symptoms and decreased KSHV viral load, suggesting that control of KSHV replication may have a role in therapy [78] . However, cidofovir, a viral DNA polymerase inhibitor with greater in-vitro activity against KSHV replication [131] failed to demonstrate comparable activity in five patients with chemotherapy-dependent KSHV-MCD [132] . In a retrospective study of 52 patients with KSHV-MCD, 12 were treated with variable antiherpesvirus therapy with or without cytotoxic therapy (but no rituximab), and only 33% of these patients obtained a sustained clinical response [133 & ]. Of eight patients who received valganciclovir, only three responded. This may be due to the fact that for B cells already infected with KSHV, ganciclovir blocks a late step in the KSHV lytic cycle and would not be expected to suppress vIL-6, an early lytic gene [134] [135] [136] .
Virus activated cytotoxic therapy
Unlike most herpesvirus-induced tumors, many KSHV-infected plasmablasts in KSHV-MCD express lytic viral genes that can provide targets for selective cytotoxicity. In addition to ganciclovir, KSHV ORF21 phosphorylates zidovudine (AZT) [128, 130] . Although antiviral activity of these drugs is through inhibition of viral DNA replication, their triphosphate moieties have cytotoxic effects at relatively high concentrations in PEL cells in which KSHV lytic genes are activated; these effects are at least additive [128] . This virus-induced cytotoxic activity is distinct from the antiviral activity of these drugs. On the basis of these findings, we performed a pilot study of high-dose AZT and VGC in 14 patients with symptomatic KSHV-MCD. Patients received AZT 600 mg every 6 h combined with VGC 900 mg every 12 h. Eighty-six percent of the treated patients obtained a clinical partial response (PR) or better, and 50% obtained a biochemical PR or better. Most patients had decreased adenopathy and splenomegaly, with 36% meeting criteria for PR or better. From baseline to time of best response, KSHV viral load, IL-6, IL-10 and CRP all decreased significantly. All five patients with detectable serum vIL-6 at baseline had decreases with therapy. These results support the activity of virus-activated cytotoxic therapy in KSHV-MCD. However, high-dose AZT combined with VGC has limitations. Toxicities are mainly hematologic, prohibiting continuous administration. Therapy was generally administered on days 1-7 of a 21-day cycle. Also, whereas long-term efficacy was observed in three of 14 patients (21%), additional therapies were required in the other patients because of persistent or recurrent KSHV-MCD symptoms [32 && ]. This regimen may be best utilized in patients with mild disease or in combination with other modalities. Future studies will be needed to define the best use of this approach.
Experimental approaches
Outcomes in therapeutic trials of rituximab and AZT and VCG have been considerably better than historical controls [31, 102] . Nonetheless, KSHV-MCD remains a challenging disease. Relapses are common, current approaches have toxicities and have not been standardized, and new effective therapies are urgently needed. With improved understanding of KSHV biology and KSHV-MCD pathogenesis, several approaches merit exploration. One is targeting IL-6 using monoclonal antibodies. Tocilizumab is a humanized anti-IL-6 receptor (gp80) antibody [137] [138] [139] , whereas siltuximab (formerly CNTO 328) [140] and sirukumab (CNTO 136) [141] are human monoclonal antibodies to IL-6. Tocilizumab and siltuximab have demonstrated activity in KSHV-negative MCD [140, 142, 143] . Although targeting human IL-6 does not directly affect vIL-6 signaling, it may still be sufficient in KSHV-MCD. Indeed, two patients with KSHV-MCD have been reported to respond to tocilizumab [143] . Tocilizumab is currently being evaluated alone and in combination with AZT and VGC (NCT01441063). Other agents worth considering for future studies include mTOR [144] inhibitors or newer immune modulators derivatives of thalidomide (IMiDs). ]. Effective therapy for KSHV-MCD, especially rituximab, may also be associated with decreased risk of subsequent development of lymphoma [145] , although this observation requires confirmation. Future studies evaluating novel therapies or rational combinations may further improve outcomes, limit toxicities and allow for personalized approaches in patients with KSHV-MCD, with concurrent KSHVassociated malignancies or with relapsed KSHV-MCD. Additional studies of biomarkers of KSHV viral reservoirs, such as KSHV viral load, or novel imaging modalities [146] may lead to improved risk stratification and allow for evaluation of consolidation therapy beyond resolution of symptoms. With improved recognition of KSHV-MCD and ongoing therapeutic advances, KSHV-MCD should continue to move from being a highly fatal disorder to a manageable manifestation of chronic KSHV infection.
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